|
|
Effect of lanthanum chloride on growth of breast
cancer cells and regulation of transcription |
Xue LI MM , Ping HE MM , Jie XIA MM , Shiwei SONG BS , Jinhai LU BM , Yunde LIU MM , |
Department of Clinical
Laboratory Sciences, Tianjin Medical University, Tianjin 300203, China; |
|
|
Abstract Lanthanum salt is a prescription drug, but its underlying functions and mechanisms are not fully understood currently. To explore the potential therapeutic value of lanthanum chloride, cytotoxicity test was applied to investigate its effects on cell proliferation. Furthermore, we observed its influence on pro-oncogene c-met by reverse transcription polymerase chain reaction (RT-PCR). In MCF-7 cell line, lanthanum chloride repressed cell proliferation at high concentration but had no significant inhibition effect on cell growth at low concentration. However, we observed that lanthanum chloride repressed c-met transcription at a low concentration. This may suggest that lanthanum chloride is a potent drug to inhibit the high expression of c-met in carcinoma cells and play a clue for inhibiting the growth and invasion of tumor.
|
Keywords
proliferation
c-met
invasion
lanthanum chloride
|
Issue Date: 05 September 2009
|
|
|
Hirano S, Suzuki K T. Exposure, metabolism, andtoxicity of rare earths and related compounds. Environ Health Perspect, 1996, 104(Suppl 1): 85―95
doi: 10.2307/3432699
|
|
Shen Q, Zhang J, Wang C. Effect of dietary rare earth elements on growth performanceof poultry. Siliao Gongye, 1991, 12(11): 21, 22 (in Chinese)
|
|
He M L, Ranz D, Rambeck W A. Study on the performance enhancing effect of rare earthelements in growing and fattening pigs. J Anim Physiol Anim Nutr (Berl), 2001, 85(7,8): 263―270
|
|
Wang K, Cheng Y, Yang X, Li R. Cell responsesto lanthanides and potential pharmacological actions of lanthanides. Met Ions Biol Syst, 2003, 40: 707―751
|
|
Evans C H. Interesting and useful biochemical properties of lanthanidesTrends Biochem Sci, 1983, 8(12): 445―449
doi: 10.1016/0968-0004(83)90032-4
|
|
Autissier V, Damment S J P, Henderson R A. Relative in vitro efficacy of the phosphate binders lanthanumcarbonate and sevelamer hydrochloride. J Pharm Sci, 2007, 96(10): 2818―2827
doi: 10.1002/jps.20956
|
|
Finn W F. Lanthanum carbonate versus standard therapy for the treatment ofhyperphosphatemia: safety and efficacy in chronic maintenance hemodialysispatients. Clin Nephrol, 2006, 65(3): 191―202
|
|
Shi Y, Gou B D, Shi Y L, Zhang T L, Wang K. Lanthanum chloride suppresses hydrogen peroxide-enhanced calcification in rat calcifyingvascular cells. Biometals, 2009, 22(2): 317―327
doi: 10.1007/s10534-008-9168-1
|
|
Anghileri L J. Effects of gallium and lanthanum on experimental tumor growth. Eur J Cancer, 1979, 15(12): 1459―1462
doi: 10.1016/0014-2964(79)90024-0
|
|
Dai Y, Li J, Li J, Yu L, Dai G, Hu A, Yuan L, Wen Z. Effects of rare earth compounds on growth and apoptosisof leukemic cell lines. In Vitro Cell DevBiol Anim, 2002, 38(7): 373―375
doi: 10.1290/1071-2690(2002)038<0373:EORECO>2.0.CO;2
|
|
Li J, Li J, Dai G, Dai Y C, Wen Z. Effects of Lanthanum chloride on growthand apoptosis of K562 leukemia cell lines. Bai Xue Bing·Lin Ba Liu, 2006, 15(6): 405―407 (in Chinese)
|
|
Heffeter P, Jakupec M A, Körner W, Chiba P, Pirker C, Dornetshuber R, Elbling L, Sutterlüty H, Micksche M, Keppler B K, Berger W. Multidrug-resistant cancer cells are preferential targetsof the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol, 2007, 73(12): 1873―1886
doi: 10.1016/j.bcp.2007.03.002
|
|
Ji Y J, Xiao B, Wang Z H, Cui M Z, Lu Y Y. The suppression effect of light rareearth elements on proliferation of two cancer cell lines. Biomed Environ Sci, 2000, 13(4): 287―292
|
|
Sato T, Hashizume M, Hotta Y, Okahata Y. Morphologyand proliferation of B16 melanoma cells in the presence of lanthanoidand Al3+ ions. Biometals, 1998, 11(2): 107―112
doi: 10.1023/A:1009273827598
|
|
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G F. Met, metastasis, motility and more. NatRev Mol Cell Biol, 2003, 4(12): 915―925
doi: 10.1038/nrm1261
|
|
Trusolino L, Bertotti A, Comoglio P M. A signaling adapter function for a6b4 integrin in thecontrol of HGF-dependent invasive growth. Cell, 2001, 107(5): 643―654
doi: 10.1016/S0092-8674(01)00567-0
|
|
Christensen J G, Burrows J, Salgia R. c-Met as a target for human cancer and characterizationof inhibitors for therapeutic intervention. Cancer Lett, 2005, 225(1): 1―26
doi: 10.1016/j.canlet.2004.09.044
|
|
Cui J J. Inhibitors targeting hepatocyte growth factor receptor and theirpotential therapeutic applications. ExpertOpin Ther Patents, 2007, 17(9): 1035―1045
doi: 10.1517/13543776.17.9.1035
|
|
Comoglio P M, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogeneaddiction and expedience. Nat Rev DrugDiscov, 2008, 7(6): 504―516
doi: 10.1038/nrd2530
|
|
Xiao B, Ji Y, Cui M. Effects of lanthanum and cerium on malignant proliferationand expression of tumor-related gene. ZhonghuaYu Fang Yi Xue Za Zhi, 1997, 31(4): 228―230 (in Chinese)
|
|
de Freitas D, Donne R L, Hutchison A J. Lanthanum carbonate--a first line phosphate binder? Semin Dial, 2007, 20(4): 325―328
doi: 10.1111/j.1525-139X.2007.00301.x
|
|
Li J, Hu G W, Ouyang D, RuiFang N, Yongqia Z, Panwen S. Effect of cerium on expression and activity of MMP-9from human carcinoma of bladder cell line. J Rare Earths (Engl), 2004, 22(2): 288―291
|
|
Zhang Y W, Su Y, Volpert O V, Vande Woude G F. Hepatocyte growth factor/scatter factor mediates angiogenesis throughpositive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A, 2003, 100(22): 12718―12723
doi: 10.1073/pnas.2135113100
|
|
Peruzzi B, Bottaro D P. Targeting the c-met signalingpathway in cancer. Clin Cancer Res, 2006, 12(12): 3657―3660
doi: 10.1158/1078-0432.CCR-06-0818
|
|
Jiang W G, Grimshaw D, Martin T A, Davies G, Parr C, Watkins G, Lane J, Abounader R, Laterra J, Mansel R E. Reduction of stromal fibroblast-inducedmammary tumor growth, by retroviral ribozyme transgenes to hepatocytegrowth factor/scatter factorand its receptor, c-MET. Clin Cancer Res, 2003, 9(11): 4274―4281
|
|
You W K, McDonald D M. The hepatocyte growth factor/c-Metsignaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep, 2008, 41(12): 833―839
|
|
Zhou H Y, Pon Y L, Wong A S. HGF/MET signaling in ovarian cancer. Curr Mol Med, 2008, 8(6): 469―480
doi: 10.2174/156652408785747933
|
|
Maulik G, Shrikhande A, Kijima T, Ma P C, Morrison P T, Salgia R. Role of the hepatocyte growth factor receptor, c-Met,in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev, 2002, 13(1): 41―59
doi: 10.1016/S1359-6101(01)00029-6
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|